Entities / Company
BioCryst Pharmaceuticals.
American pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 58
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
ORLADEYO has seen significant revenue growth, and new treatments are being evaluated for their potential impact on the demand for HAE sufferers.Well supported10 reports1 development inside
-
BioCryst Pharmaceuticals is closing its research center in Hoover, while maintaining facilities in Alabama.Some support1 report1 development inside
-
BioCryst Pharmaceuticals traded on the NASDAQ electronic stock exchange on September 12, 2026.Some support2 reports
-
Amgen is reportedly interested in BioCryst Pharmaceuticals, which operates in the rare-disease market, as a potential acquisition target.Some support1 report
-
BioCryst Pharmaceuticals, Torii Pharmaceutical Co., Ltd., and Ascletis Pharma are involved in collaborations and market comparisons.Some support1 report
Gone quiet
No new reports in 90+ days-
Analyst target price targets were adjusted for multiple companies, including American Express, BioCryst Pharmaceuticals, and American Airlines Group.Some support2 reports
-
MarketBeat aggregated analyst ratings and Cantor Fitzgerald issued research reports for BioCryst Pharmaceuticals.Some support5 reports
-
BioCryst Pharmaceuticals announced a strategic shift toward external innovation and capital efficiency.Some support2 reports
-
BioCryst Pharmaceuticals began using LinkedIn for company updates.Some support3 reports
-
BioCryst Pharmaceuticals is noted as benefiting from Trump-era tariffs on September 2, 2025.Some support4 reports1 development inside
-
Grupo Aeroportuario del Sureste and BioCryst Pharmaceuticals were featured together in a stock screening article on June 26, 2025.Speculative2 reports
-
BioCryst Pharmaceuticals adhered to Nasdaq Listing Rule 5635(c)(4) on September 3, 2025.Some support4 reports
-
Babar Ghias was appointed as the Chief Financial Officer (CFO) of BioCryst Pharmaceuticals.Speculative1 report
-
BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company.Some support1 report2 developments inside
-
AscellaHealth supports rare disease manufacturers, while BioCryst Pharmaceuticals details its leadership structure with Quill, Gayer, and Oldham.Some support1 report
-
Jon Stonehouse is retiring as CEO of BioCryst Pharmaceuticals, and Charlie Gayer will assume the role.Some support1 report
-
BioCryst Pharmaceuticals is based in Durham, North Carolina, according to data generated by Automated Insights.Some support1 report
-
Incepta Pharmaceuticals and BioCryst Pharmaceuticals were ranked in the Medical – Drugs industry as of August 13, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around BioCryst Pharmaceuticals this week
News at the entities that move BioCryst Pharmaceuticals most-
Royal Bank of Canada TransactionalRoyal Bank of Canada dropped its price objective for Crown Castle Inc., while Citigroup reiterated an outperform rating.Moves BioCryst Pharmaceuticals
-
Amgen TransactionalMSKCC director Rudin presented trial data involving Amgen on October 25, 2026.Moves BioCryst Pharmaceuticals
-
Europe OperationalHill and Carl Cannon offer critiques and alternatives regarding European welfare state and economic issues.Moves BioCryst Pharmaceuticals
-
Nasdaq StructuralVMware's stock performance was tracked on the Nasdaq exchange on October 25, 2026.Moves BioCryst Pharmaceuticals
-
MarketBeat Mentioned togetherMarketBeat released analyst recommendations for small-cap communication services companies Optimum Communications and Criteo.Moves BioCryst Pharmaceuticals
-
Cantor Fitzgerald Mentioned togetherThe event reports that Brooke Rollins serves as Trump's Agriculture Secretary and notes that Lutnick previously ran Cantor Fitzgerald.Moves BioCryst Pharmaceuticals
Connections
The 11 strongest of 58, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Royal Bank of Canada Transactional
RBC actively managed its investment in BioCryst stock by adjusting holdings and issuing research notes.
-
Hoover Transactional
BioCryst Pharmaceuticals is concluding operations by closing its research center in the area of Hoover.
-
Amgen Transactional
Amgen is cited as a potential acquirer of BioCryst Pharmaceuticals.
-
Europe Operational
BioCryst's market access, sales, and global expansion are directly tied to the regulatory and commercial environment of Europe.
-
LinkedIn Mentioned together
BioCryst Pharmaceuticals utilizes LinkedIn as a platform for corporate updates, following company news, and investor relations.
-
Nasdaq Structural
BioCryst Pharmaceuticals is a publicly traded company listed on the Nasdaq stock exchange.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides financial research reports and analyst coverage on BioCryst Pharmaceuticals.
-
AstraZeneca Shared context
Both companies operate within the rare-disease market sector.
Show all 11 connections
-
MarketBeat Mentioned together
MarketBeat aggregates analyst ratings and consensus reports regarding BioCryst Pharmaceuticals.
-
Alabama Shared context
BioCryst Pharmaceuticals has a company facility located within the state of Alabama.
-
Birmingham Mentioned together
The single snapshot provides generic information about BioCryst Pharmaceuticals but does not mention Birmingham, making the relationship unconfirmed.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
3 events- BioCryst Pharmaceuticals is closing its research center in Hoover, while maintaining facilities in Alabama.
- Amgen is reportedly interested in BioCryst Pharmaceuticals, which operates in the rare-disease market, as a potential acquisition target.
- BioCryst Pharmaceuticals, Torii Pharmaceutical Co., Ltd., and Ascletis Pharma are involved in collaborations and market comparisons.
June 2026
14 events- ORLADEYO has seen significant revenue growth, and new treatments are being evaluated for their potential impact on the demand for HAE sufferers.
- Analyst target price targets were adjusted for multiple companies, including American Express, BioCryst Pharmaceuticals, and American Airlines Group.
- MarketBeat aggregated analyst ratings and Cantor Fitzgerald issued research reports for BioCryst Pharmaceuticals.
- BioCryst Pharmaceuticals announced a strategic shift toward external innovation and capital efficiency.
- BioCryst Pharmaceuticals began using LinkedIn for company updates.
- BioCryst Pharmaceuticals is noted as benefiting from Trump-era tariffs on September 2, 2025.
- Grupo Aeroportuario del Sureste and BioCryst Pharmaceuticals were featured together in a stock screening article on June 26, 2025.
- BioCryst Pharmaceuticals adhered to Nasdaq Listing Rule 5635(c)(4) on September 3, 2025.
- Babar Ghias was appointed as the Chief Financial Officer (CFO) of BioCryst Pharmaceuticals.
- BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company.
- AscellaHealth supports rare disease manufacturers, while BioCryst Pharmaceuticals details its leadership structure with Quill, Gayer, and Oldham.
- Jon Stonehouse is retiring as CEO of BioCryst Pharmaceuticals, and Charlie Gayer will assume the role.
- BioCryst Pharmaceuticals is based in Durham, North Carolina, according to data generated by Automated Insights.
- Incepta Pharmaceuticals and BioCryst Pharmaceuticals were ranked in the Medical – Drugs industry as of August 13, 2025.